The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Livtencity



Takeda Pharmaceuticals International AG Ireland BranchEU/1/22/1672/001-002

Main Information

Trade NameLivtencity
Active SubstancesMaribavir
Dosage FormFilm-coated tablet
Licence HolderTakeda Pharmaceuticals International AG Ireland Branch
Licence NumberEU/1/22/1672/001-002

Group Information

ATC CodeJ05AX10 maribavir

Status

License statusAuthorised
Licence Issued09/11/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal products on restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back